Original Research
Published on 04 Jul 2023
Manipulating RKIP reverses the metastatic potential of breast cancer cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1189350
- 1,482 views
- 2 citations
Type at least 3 characters
1,724 articles
Articles
Brief Research Report
Published on 03 Jul 2023
Genomic determinants in advanced endometrial cancer patients with sustained response to hormonal therapy- case series and review of literature
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1188028
- 1,649 views
Review
Published on 03 Jul 2023
T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1168622
- 8,132 views
- 2 citations
Review
Published on 30 Jun 2023
Paper-based biosensors as point-of-care diagnostic devices for the detection of cancers: a review of innovative techniques and clinical applications
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1131435
- 3,783 views
- 7 citations
Correction
Published on 27 Jun 2023
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1236311
- 993 views
Correction
Published on 27 Jun 2023
Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1218746
- 812 views
Original Research
Published on 23 Jun 2023
An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1207068
- 4,302 views
- 11 citations
Review
Published on 23 Jun 2023
Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1110207
- 5,424 views
- 5 citations
Mini Review
Published on 20 Jun 2023
Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1197502
- 2,843 views
- 1 citation
Original Research
Published on 19 Jun 2023
Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1192472
- 1,858 views
- 1 citation
Original Research
Published on 19 Jun 2023
Lestaurtinib inhibits Citron kinase activity and medulloblastoma growth through induction of DNA damage, apoptosis and cytokinesis failure
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1202585
- 2,030 views
Review
Published on 19 Jun 2023
The role of Vps4 in cancer development
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1203359
- 4,703 views
- 2 citations
Clinical Trial
Published on 14 Jun 2023
A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1202544
- 2,566 views
- 2 citations
Review
Published on 14 Jun 2023
The use of plant-derived exosome-like nanoparticles as a delivery system of CRISPR/Cas9-based therapeutics for editing long non-coding RNAs in cancer colon cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1194350
- 4,009 views
- 5 citations
Original Research
Published on 13 Jun 2023
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1192208
- 2,284 views
Original Research
Published on 12 Jun 2023
Early in vitro evidence indicates that deacetylated sialic acids modulate multi-drug resistance in colon and lung cancers via breast cancer resistance protein
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1145333
- 3,600 views
- 4 citations